Mahama to commission DNA testing, vaccine development laboratories at Noguchi
President John Dramani Mahama will commission new human DNA testing laboratories and a dedicated vaccine development facility at the Noguchi Memorial Institute for Medical Research (NMIMR) on…
Journalist
Published 2 min read

President John Dramani Mahama will commission new human DNA testing laboratories and a dedicated vaccine development facility at the Noguchi Memorial Institute for Medical Research (NMIMR) on Wednesday, November 18.
The ceremony is scheduled for 2:00 p.m. at the institute in Accra, according to an announcement by the Ministry of Health on its Facebook page on Tuesday.
"Tomorrow, President John Dramani Mahama will commission new DNA Laboratories for human testing, alongside a dedicated laboratory for vaccine development at the Noguchi Memorial Institute for Medical Research (NMIMR)," the Ministry said.
The Ministry described the investment as an important step in building Ghana's scientific and research capacity. It said recent experiences had shown the need for the country to carry out critical laboratory tests at home instead of sending samples abroad. It also said the facilities would improve Ghana's preparedness for public health emergencies.
Background
Noguchi, established in 1979, is named after the Japanese scientist Hideyo Noguchi, and Japan has reaffirmed its support for the institute through technical collaboration, funding and research partnerships. In July, President Mahama said Noguchi is the only laboratory in Ghana currently dedicated to pathogen research.
The DNA facilities follow an earlier government commitment. At the institute's 2025 Annual Research Meeting, Health Minister Kwabena Mintah Akandoh announced that the President had approved the procurement of an advanced DNA diagnostics machine for high-precision testing and pathogen detection.
The vaccine facility comes as the government pushes to build local vaccine production. In August 2025, President Mahama allocated $50 million to the National Vaccine Institute (NVI) to support vaccine manufacturing. The NVI's chief executive, Dr Sodzi Sodzi-Tettey, said last month that the institute had set up an mRNA laboratory at Noguchi this year, making Ghana one of only five African countries with the technology. He said the laboratory represents a shift from dependence on imported vaccines toward the capacity to develop and manufacture them locally.
Dr Sodzi-Tettey has also said Ghana is aiming to produce its first locally manufactured vaccine, a tetanus-diphtheria vaccine, next year, through a partnership between the NVI, Atlantic Lifesciences, Noguchi and Indonesia's PT Bio Farma.
Noguchi's vaccine work is not new. Years ago, the institute hosted a Phase 1B trial of a Lassa fever DNA vaccine, the first vaccine trial for the disease in West Africa. During the COVID-19 pandemic, it also received $800,000 worth of sequencing equipment to support pathogen research and vaccine design.
Further details of the new laboratories, including their capacity and cost, are expected at the commissioning.
Get the AfroAsia Media newsletter
The day's top stories from Africa and Asia, straight to your inbox.
Comments
0 comments
Loading…